About Apposite Capital
Apposite Capital is a venture capital firm founded in 2006. It is primarily based out of London, United Kingdom. As of Apr 2019, Apposite Capital has invested in 18 companies. It primarily invests in Series A round in United Kingdom based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series A round of Mirada Medical Overall, Apposite Capital portfolio has seen 10 acquisitions including key companies like Ambrx, Ultherapy and Ambit Biosciences. A lot of funds co-invest with Apposite Capital, with names like SR One sharing a substantial percentage of its portfolio. Apposite Capital has team of 16 people including 1 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 3 more
Portfolio Acquisitions
Apposite Capital's List of Top Investments
Apposite Capital has a portfolio of 18 companies. Their most notable investments are in NIMGenetics and Mirada Medical.Their portfolio spans across United Kingdom, United States, Denmark and 2 more locations. They have invested in Life Sciences, High Tech, HealthTech and 4 other sectors, across stages such as Series A, Series B and 3 more. Here is the list of top investments by Apposite Capital:1. Ambrx
Developer of Antibody-drug conjugates to treat cancers, metabolic disorders, and cardiovascular disorders. The company has developed Engineered Precision Biologics (EPBs) by using proprietary genetic code technology to produce antibody-drug conjugates (ADCs) and immuno-oncology conjugates (IOCs) for treating cancers. The product pipeline includes ARX788 an anti-HER2 ADC currently being studied in breast cancer, gastric cancer, and other solid tumors, ARX517 for prostate cancer, and more. They have developed immuno-oncology conjugates for NASH, heart failure, and prostate cancer
Key facts about Ambrx
- Founded Year: 2003
- Location: San Diego (United States)
- Annual Revenue: $7.4M as on Dec 31, 2022
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $346M
- Employee Count: 61 as on Mar 31, 2026
- Investors: Glynn Capital, Fidelity Investments and 23 Others
- Latest Funding Round: Series E, Nov 09, 2020, $*****
- Highlight: Acquired
2. Ultherapy
Non-invasive skin lifting and tightening treatments using ultrasound technology. The company specializes in non-surgical skin lifting and tightening treatments using micro-focused ultrasound with real-time visualization. Their flagship treatment, is FDA-cleared to lift the eyebrow, neck, chin, and improve décolleté lines and wrinkles. It stimulates collagen and elastin production for natural-looking, long-lasting results with no downtime. The treatment is personalized, safe, and effective for all skin tones. They offer a non-invasive alternative to traditional facelifts, providing visible lifting and skin rejuvenation. The company focuses on aesthetic medicine, offering a single-session treatment with long-lasting effects. They provide resources for finding licensed physicians and accessing product information.
Key facts about Ultherapy
- Founded Year: 2004
- Location: Mesa (United States)
- Stage: Acquired
- Total Funding till date: $39.7M
- Employee Count: 104 as on Dec 31, 2015
- Investors: Vensana Capital, New Enterprise Associates and 3 Others
- Latest Funding Round: Series C, Feb 08, 2011, $*****
- Highlight: Acquired
Biopharmaceutical company discovering and developing kinase inhibitor drugs for oncology and autoimmune diseases. They focus on unmet medical needs by inhibiting kinases, crucial drivers in these diseases. Their pipeline features internally discovered programs targeting validated kinase targets. They leverage their kinase expertise to discover, optimize, and develop a sustainable pipeline of small molecule kinase inhibitors. Their research and development efforts are geared towards creating innovative therapies. They are dedicated to advancing scientific knowledge and translating it into effective treatments. They are focused on drug discovery, medicinal chemistry, structure-based drug design, PK/ADME, and in vivo pharmacology.
Key facts about Ambit Biosciences
- Founded Year: 2000
- Location: San Diego (United States)
- Stage: Acquired
- Total Funding till date: $163M
- Employee Count: 55 as on Dec 31, 2015
- Investors: Aisling Capital, Foresite Capital and 15 Others
- Latest Funding Round: Series E, Nov 07, 2012, $*****
- Highlight: Acquired
4. CrestOptics
Manufacturer of microscopy devices for multiple diagnostic applications. The company has developed an X-Light V2 spinning disk model device that helps in viewing live and fixed cell imaging. It also provides X-Light NIR confocal system that allows performing fluorescence imaging in the optical range 700-1600nm. Other products include X-Light 20K rpm, X-Light V2 L-FOV, VCS Super resolutions model, and many more.
Key facts about CrestOptics
- Founded Year: 2010
- Location: Rome (Italy)
- Annual Revenue: €16.2M as on Dec 31, 2024
- Stage: Acquired
- Employee Count: 104 as on Jul 01, 2024
- Investors: Xyence Capital and Apposite Capital
- Highlight: Acquired
5. Wellpartner
Wellpartner provides services to complement their client's existing pharmacy solutions and help achieve better health outcomes. Some of the service offerings are: AccessConvergence and 340BAccess. AccessConvergence provides 340B program management combining claims administration, specialty pharmacy dispensing and health plan coordination. Through its nationally licensed URAC, ACHC and VIPPS accredited specialty pharmacy, the firm also dispenses pharmaceuticals to selected patients of these hospitals and clinics
Key facts about Wellpartner
- Founded Year: 2000
- Location: Tualatin (United States)
- Stage: Series D
- Total Funding till date: $37.6M
- Employee Count: 89 as on Dec 31, 2022
- Investors: Mediphase Venture Partners, Burrill and Company and 6 Others
- Latest Funding Round: Series D, Aug 01, 2008, $*****
Apposite Capital's Year-on-Year Investment Trends
Apposite Capital has invested in 26 companies over the last 20 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in Mirada Medical and most recent follow-on round was in Ambit Biosciences.Apposite Capital's Investments by Stage
Apposite Capital has made 4 investments in Series A stage with an average round size of $17M, 2 investments in Series B stage with an average round size of $14.2M, 2 investments in Series C stage with an average round size of $32.7M, 1 investment in Seed stage and 1 investment in Series D stage with an average round size of $49.3M.Stage of entry | No. of Investments |
|---|---|
Series A | 4 |
Series B | 2 |
Series C | 2 |
Seed | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Apposite Capital's Investments by Sector
Apposite Capital has a diverse portfolio, with companies operating in the Life Sciences, Healthcare, High Tech, Enterprise Applications and HealthTech. Notably, it has invested in 10 Tech companies, 9 Enterprise (B2B) companies, 4 Software companies and at least 3 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 8 |
Healthcare | 2 |
High Tech | 2 |
Enterprise Applications | 1 |
HealthTech | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Apposite Capital's Investments by Geography
Apposite Capital has made most investments in United Kingdom (5), followed by United States where it has made 4 investments.Country | No. of Investments |
|---|---|
United Kingdom | 5 |
United States | 4 |
Spain | 1 |
Note: We have considered here, only first round of investments
Apposite Capital's recent investments
Apposite Capital has not made any investment in 2026 so far.Here are the most recent investments by Apposite Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 08, 2019 | United Kingdom | Series A | 8395 | - | |
Jan 02, 2019 | United Kingdom | Seed | 5386 | - | |
May 10, 2017 | Spain | Series A | 7238 | - | |
May 09, 2016 | United Kingdom | Series A | 1771 | - | |
Mar 25, 2014 | United States | Series B | 7815 | [+5] |
Acquired companies in Apposite Capital's Portfolio
10 companies from Apposite Capital's portfolio have been acquired. The most recent acquisition were NIMGenetics in Jan 2025 by Veritas Genetics.Here are Apposite Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 20, 2025 | May 10, 2017 | Series A | 6062 | |
Jan 08, 2024 | Jul 05, 2006 | Series C | 2456 | |
Aug 21, 2023 | Mar 25, 2014 | Series B | 8288 | |
Nov 11, 2021 | - | - | 3460 | |
Jul 01, 2015 | - | - | 7637 |
_1557490524091.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of Apposite Capital
Apposite Capital has a team of 16 members including 1 Partner and 4 Principals located in United Kingdom. Apposite Capital's team does not sit on the board of any company as of now.Here is a list of top team members in Apposite Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | London | - | ||
Principal | London | - | - | |
Principal | London | - | ||
Principal | London | - | ||
Principal | London | - | - |
Co-investors of Apposite Capital
Over the past 20 years, 44 investors have co-invested in Apposite Capital's portfolio companies. This includes only funds.
- Invested before Apposite Capital: Europa, CMEA Capital and 7 others have invested in rounds before Apposite Capital. There are 2 companies where Europa has invested before Apposite Capital and 1 company where CMEA Capital has invested before Apposite Capital.
- Top Co-investors of Apposite Capital: 19 investors entered a company along with Apposite Capital. These include investors like SR One (2 companies).
- Invested after Apposite Capital: A total of 16 investors have invested in Apposite Capital's portfolio after their investments. Top Investors include Fosun Pharmaceutical (1 company), Sinopharm Capital (1 company) and Apricot Capital (1 company).
Recent News related to Apposite Capital
•
Kelso Pharma secures £140 million of acquisition fundingInsider•Mar 27, 2025•Kelsopharma.com, Alturix, Apposite Capital
•
•
Private equity-backed Swanton Care expands with acquisitionInsider Media•Nov 13, 2024•Swanton Care, Apposite Capital
•
QT Imaging Holdings Announces Favorable Amendment of Convertible Promissory NoteBusiness Wire•Sep 30, 2024•Apposite Capital
•
1MED Acquires French Clinical Research Evamed, Accelerating Geographic Expansion
Asklepios Advisors•Sep 07, 2023•1MED, Evamed, Apposite Capital, Asklepios Advisors
•
PE-backed care provider completes eighth acquisitionInsider Media•Oct 18, 2022•Apposite Capital, Swanton Care, Douneanddeanston
•
•
•
•
Private Equity Investor Apposite Capital Acquires Ticino Based 1medStartupticker•Jun 04, 2021•1MED, Apposite Capital
